



Beginning July 1, 2020, Truvada (emtricitabine and tenofovir disoproxil fumarate 200-300 mg) for PrEP[®] (pre-exposure prophylaxis), a prescription drug that can help reduce the risk of human immunodeficiency virus (HIV), will be added to the ACA Preventive Drug List. Therefore, Blue Cross and Blue Shield of Alabama's ACA Preventive Drug Lists will be updated to cover this drug as a preventive service at 100% with no member cost sharing.

This addition to the ACA Preventive Drug List comes from the United States Preventive Services Task Force's (USPSTF) recommendation that "clinicians offer PrEP with effective antiretroviral therapy to persons who are at high risk of HIV acquisition." Truvada is one of the two agents that are FDA-approved and have shown effectiveness when used in the prevention of HIV.

Truvada will be covered as a preventive service at 100% with no member cost sharing only if the member's claims history does NOT present previous or additional HIV treatments.

Blue Cross has incorporated a Lookback Management Strategy in order to determine appropriate member coverage of Truvada:

- When a prescription for Truvada 200-300mg is presented at the pharmacy, a lookback is applied to the member's claims history.
- The lookback is used to determine if the member has prescriptions for any HIV therapies other than Truvada in their claims history.
 - ▶ If other HIV therapy claims appear in their claims history, Truvada will not be considered as a "preventive medication" and will process at the appropriate tier and the member will pay the applicable member cost share.
 - ▶ If no other HIV therapy claims appear in their claims history, Truvada will process as a "preventive medication" at 100% with no member cost share.